As of November 7, 2026, 2 holders' latest Schedule 13D or 13G filings report owning 5% or more of Bolt Biotherapeutics, Inc. The largest reported stake is Coastlands Capital LP's, at 17.5%. 8 filings are on record since August 14, 2025 (Schedule 13G, November 6, 2026).
Who owns Bolt Biotherapeutics, Inc.?
Sell to companies like Bolt Biotherapeutics, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · Reporting person: Coastlands Capital LP · Sole voting: 0 · Shared voting: 412,416 · Sole dispositive: 0 · Shared dispositive: 412,416 · SCHEDULE 13G, 2026-11-06
- · Reporting person: Renaissance Technologies LLC · Sole voting: 98,625 · Shared voting: 0 · Sole dispositive: 98,625 · Shared dispositive: 0 · SCHEDULE 13G, 2026-08-13
- · Reporting person: Nan Fung Group Holdings Limited · Sole voting: 0 · Shared voting: 87,486 · Sole dispositive: 0 · Shared dispositive: 87,486 · SCHEDULE 13D/A, 2026-02-26
- · Holder: Pivotal bioVenture Partners Fund I, L.P. · Percent: 6.7% · SCHEDULE 13D/A
- · Reporting person: Vivo Capital Fund VIII, L.P. · Sole voting: 0 · Shared voting: 0 · Sole dispositive: 0 · Shared dispositive: 0 · SCHEDULE 13G/A, 2026-02-13
Bolt Biotherapeutics, Inc. has 8 Schedule 13D or 13G filings on record since 2025-08-14. 2 holders' latest filing reports 5% or more of common stock, par value $0.00001 per share. Each figure below is the holder's own, as filed, with the filing linked.
Layoffs on record: about 20 jobs, latest 2025-10-02 (layoff filings and notices).
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| Coastlands Capital LP | 17.5% | 412,416 | SCHEDULE 13G, 2026-11-06 | 2026-10-30 |
| Renaissance Technologies LLC | 5.13% | 98,625 | SCHEDULE 13G, 2026-08-13 | 2026-06-24 |
| Pivotal bioVenture Partners Fund I, L.P. | 4.6% | 52,556 | SCHEDULE 13D/A, 2026-02-26 | 2026-02-24 |
| Vivo Panda Fund, L.P. | 3.8% | 72,414 | SCHEDULE 13G/A, 2026-02-13 | 2025-12-31 |
| Tang Capital Management, LLC | 3.5% | 66,879 | SCHEDULE 13G/A, 2025-11-14 | 2025-09-30 |
Holding shares or following this stake? See who's behind Bolt Biotherapeutics, Inc. and the warning signs.
Free to see. No signup.
Keep reading
More on Bolt Biotherapeutics, Inc. and the records around it.
Bolt Biotherapeutics, Inc. elsewhere on the record
- Leadership changes Oct 2026
- Layoff notices Oct 2025
- Who owns it
Companies that share a holder
- Nan Fung Group Holdings Limited also filed stake reports on 2 other companies: Evommune, Inc. (Feb 2026), Oculis Holding AG (Nov 2025)
- Coastlands Capital LP also filed stake reports on 16 other companies: Sutro Biopharma, Inc. (Nov 2026), Kalaris Therapeutics, Inc. (Oct 2026), Frazier Life Sciences Acquisition Corp. II (Oct 2026)
- TANG CAPITAL MANAGEMENT, LLC also filed stake reports on 33 other companies: EyePoint, Inc. (Oct 2026), Skye Bioscience, Inc. (Oct 2026), Nano Dimension Ltd. (Aug 2026)
Watch Bolt Biotherapeutics, Inc.
Get an email when Bolt Biotherapeutics, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Bolt Biotherapeutics, Inc.?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Bolt Biotherapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Bolt Biotherapeutics, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
10 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Voting and dispositive power, as filed
| Reporting person | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Filing |
|---|---|---|---|---|---|
| Coastlands Capital LP | 0 | 412,416 | 0 | 412,416 | SCHEDULE 13G, 2026-11-06 |
| Coastlands Capital Partners LP | 0 | 412,416 | 0 | 412,416 | SCHEDULE 13G, 2026-11-06 |
| Coastlands Capital GP LLC | 0 | 412,416 | 0 | 412,416 | SCHEDULE 13G, 2026-11-06 |
| Coastlands Capital LLC | 0 | 412,416 | 0 | 412,416 | SCHEDULE 13G, 2026-11-06 |
| Matthew D. Perry | 0 | 412,416 | 0 | 412,416 | SCHEDULE 13G, 2026-11-06 |
| Renaissance Technologies LLC | 98,625 | 0 | 98,625 | 0 | SCHEDULE 13G, 2026-08-13 |
| Renaissance Technologies Holdings Corporation | 98,625 | 0 | 98,625 | 0 | SCHEDULE 13G, 2026-08-13 |
| Nan Fung Group Holdings Limited | 0 | 87,486 | 0 | 87,486 | SCHEDULE 13D/A, 2026-02-26 |
| NF Investment Holdings Limited | 0 | 87,486 | 0 | 87,486 | SCHEDULE 13D/A, 2026-02-26 |
| Pivotal bioVenture Partners Fund I, L.P. | 0 | 52,556 | 0 | 52,556 | SCHEDULE 13D/A, 2026-02-26 |
| Pivotal bioVenture Partners Fund I G.P., L.P. | 0 | 52,556 | 0 | 52,556 | SCHEDULE 13D/A, 2026-02-26 |
| Pivotal bioVenture Partners Fund I U.G.P. Ltd. | 0 | 52,556 | 0 | 52,556 | SCHEDULE 13D/A, 2026-02-26 |
| Pivotal Partners Ltd | 0 | 52,556 | 0 | 52,556 | SCHEDULE 13D/A, 2026-02-26 |
| Pivotal Life Sciences Holdings Limited | 0 | 52,556 | 0 | 52,556 | SCHEDULE 13D/A, 2026-02-26 |
| Nan Fung Life Sciences Holdings Limited | 0 | 82,486 | 0 | 82,486 | SCHEDULE 13D/A, 2026-02-26 |
| Permwell Management Limited | 0 | 5,000 | 0 | 5,000 | SCHEDULE 13D/A, 2026-02-26 |
| NFLS Beta Limited | 0 | 29,930 | 0 | 29,930 | SCHEDULE 13D/A, 2026-02-26 |
| NFLS Platform Holdings Limited | 0 | 29,930 | 0 | 29,930 | SCHEDULE 13D/A, 2026-02-26 |
| Vivo Capital Fund VIII, L.P. | 0 | 0 | 0 | 0 | SCHEDULE 13G/A, 2026-02-13 |
| Vivo Capital Surplus Fund VIII, L.P. | 0 | 0 | 0 | 0 | SCHEDULE 13G/A, 2026-02-13 |
| Vivo Capital VIII, LLC | 0 | 0 | 0 | 0 | SCHEDULE 13G/A, 2026-02-13 |
| Vivo Panda Fund, L.P. | 72,414 | 0 | 72,414 | 0 | SCHEDULE 13G/A, 2026-02-13 |
| Vivo Panda, LLC | 72,414 | 0 | 72,414 | 0 | SCHEDULE 13G/A, 2026-02-13 |
The latest filing identifies Bolt Biotherapeutics, Inc. by CUSIP 097702203 and gives its principal executive office as 900 Chesapeake Drive, Redwood City, CA 94063 (SCHEDULE 13G, 2026-11-06).
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-08-14 | Tang Capital Management, LLC | 8.7% | SCHEDULE 13G/A |
| 2025-11-14 | Tang Capital Management, LLC | 3.5% | SCHEDULE 13G/A |
| 2025-11-14 | Tang Capital Management, LLC | 3.5% | SCHEDULE 13G/A |
| 2026-02-13 | Vivo Panda Fund, L.P. | 3.8% | SCHEDULE 13G/A |
| 2026-02-17 | Pivotal bioVenture Partners Fund I, L.P. | 6.7% | SCHEDULE 13D/A |
| 2026-02-26 | Pivotal bioVenture Partners Fund I, L.P. | 4.6% | SCHEDULE 13D/A |
| 2026-08-13 | Renaissance Technologies LLC | 5.13% | SCHEDULE 13G |
| 2026-11-06 | Coastlands Capital LP | 17.5% | SCHEDULE 13G |
Questions about who owns Bolt Biotherapeutics, Inc.
Who owns Bolt Biotherapeutics, Inc.?
On this page, 2 holders' latest ownership filings report 5% or more of Bolt Biotherapeutics, Inc.: Coastlands Capital LP (17.5%, Schedule 13G, filed 2026-11-06) and Renaissance Technologies LLC (5.13%, Schedule 13G, filed 2026-08-13).
Who are the largest shareholders of Bolt Biotherapeutics, Inc.?
By the share each holder's latest filing reports, the largest holders of Bolt Biotherapeutics, Inc. on this page are Coastlands Capital LP (17.5%) and Renaissance Technologies LLC (5.13%).
When did Coastlands Capital LP buy into Bolt Biotherapeutics, Inc.?
The filings give report dates, not purchase dates. The earliest filing from Coastlands Capital LP on this page is the Schedule 13G, filed 2026-11-06, reporting 17.5%.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 8 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Also on the record for Bolt Biotherapeutics, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| October 23, 2026 | Leadership change: Sheila Gujrathi appointed, Director, and 1 more | — | Leadership changes | Source |
Tools for this story
Each opens in a new tab, filled in for Bolt Biotherapeutics, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.